Investment in NRG Therapeutics to generate novel molecules targeting mitochondrial dysfunction on track

8 Jan 2020

Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with NRG Therapeutics Ltd to develop novel drugs that can protect mitochondria and thereby slow the progression of Parkinson’s.  
 
Mitochondria are tiny batteries present inside cells that provide the essential energy they need to survive and function. Previous research has shown that mitochondria inside the brain cells affected in Parkinson’s stop working properly. 

 

In July 2019, Parkinson’s UK announced funding of £1million to create novel, small molecules that are likely to enter the brain and protect the mitochondria within dopamine-producing cells. 
 
Jan Kulagowski, Drug Discovery Manager and leader of the programme at Parkinson’s UK, comments: “We’re pleased to report that this project is on track and we’re very happy with the progress made so far which includes generating some novel molecules. Following a mid-stage review with our Drug Discovery Advisory Panel we are delighted to release the second tranche of our investment to continue with the next stage of the work plan. 

 

“Molecules identified as the most promising in this first, exploratory phase will be taken to the next stage in which we will build in the sort of properties required for a drug to treat Parkinson's. Ultimately, our goal is to take this project forward to develop new drugs that can help people with Parkinson’s.”

 

Neil Miller, CEO of NRG Therapeutics, comments: “I am delighted with the progress we have made during the last 6 months. Release of the second tranche of investment from Parkinson's UK will enables NRG Therapeutics to continue its research efforts towards our ultimate goal of delivering a novel treatment for Parkinson’s.”

 

 

ENDS

 

Parkinson’s UK is the largest charitable funder of Parkinson's research in Europe.   

 

The aim of its Virtual Biotech programme, of which its partnership with NRG Therapeutics is a part, is to invest £22million ($29million) by the end of 2021 to support projects and companies that are driving towards important new treatments with the potential to transform the lives of people with Parkinson’s.

 

​Parkinson’s UK is looking for partners to help it create a portfolio of projects that can attract further investment and take successful projects into the later stages of drug development and trials.

 

For more information visit: www.parkinsonsvirtualbiotech.co.uk

Please reload

© Parkinson’s UK, July 2019. Parkinson’s is the operating name of the Parkinson’s Disease Society of the United Kingdom. A charity registered in England and Wales (258197) and in Scotland (SC037554)

Parkinson's UK